Literature DB >> 21592720

Acetabular revision total hip arthroplasty using an impacted morselized allograft and a cementless cup: minimum 10-year follow-up.

Joong-Myung Lee1, Hee-Tae Nam.   

Abstract

This study was undertaken to analyze the clinical and radiologic results of acetabular revision arthroplasty using an impacted morselized allograft and a cementless cup and was performed on 71 hips of 62 patients who were followed up for a minimum of 10 years (10 years to 14 years 8 months; mean, 12 years). The acetabular bone defects were classified using the American Academy of Orthopaedic Surgeons Committee on the Hip and Paprosky classifications. Cementless hemispherical cups were inserted via a press-fit technique, using an impacted morselized allograft. The mean Harris hip score at the last follow-up visit was 92. Only 3 cases were re-revised, and the 12-year survival rate was thus 95.8%. The study shows that acetabular revision arthroplasty using an impacted morselized allograft and a cementless cup is an excellent treatment option.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21592720     DOI: 10.1016/j.arth.2011.03.035

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  11 in total

1.  Contact between the acetabulum and dome of a Kerboull-type plate influences the stress on the plate and screw.

Authors:  Katsutoshi Hara; Nobuhiro Kaku; Tomonori Tabata; Hiroshi Tsumura
Journal:  Eur J Orthop Surg Traumatol       Date:  2015-03-08

2.  Reconstruction options for acetabular revision.

Authors:  Erica D Taylor; James A Browne
Journal:  World J Orthop       Date:  2012-07-18

3.  Long Term Outcomes of Total Hip Arthroplasty in Young Patients under 30.

Authors:  Emilios E Pakos; Nikolaos K Paschos; Theodoros A Xenakis
Journal:  Arch Bone Jt Surg       Date:  2014-09-15

4.  Revision of Total Hip Arthroplasty with Acetabular Bone Defects: Are Biological Grafts Really Better than Synthetic Bone Graft Substitutes?

Authors:  Luca Costanzo Comba; Enrico Bellato; Danilo Colombero; Lorenzo Mattei; Antongiulio Marmotti; Filippo Castoldi
Journal:  Arch Bone Jt Surg       Date:  2022-07

Review 5.  Uncemented Cups and Impaction Bone Grafting for Acetabular Bone Loss in Revision Hip Arthroplasty: A Review of Rationale, Indications, and Outcomes.

Authors:  Rocco D'Apolito; Luigi Zagra
Journal:  Materials (Basel)       Date:  2022-05-23       Impact factor: 3.748

6.  Influence of the volume of bone defect, bone grafting methods, and hook fixation on stress on the Kerboull-type plate and screw in total hip arthroplasty: three-dimensional finite element analysis.

Authors:  Nobuhiro Kaku; Katsutoshi Hara; Tomonori Tabata; Hiroshi Tsumura
Journal:  Eur J Orthop Surg Traumatol       Date:  2014-06-27

7.  Fate of bone grafting for acetabular defects in total hip replacement.

Authors:  Anil Thomas Oommen; Vignesh Prasad Krishnamoorthy; Pradeep Mathew Poonnoose; Ravi Jacob Korula
Journal:  Indian J Orthop       Date:  2015 Mar-Apr       Impact factor: 1.251

8.  Porous titanium particles for acetabular reconstruction in total hip replacement show extensive bony armoring after 15 weeks. A loaded in vivo study in 10 goats.

Authors:  Lucas H B Walschot; René Aquarius; Nico Verdonschot; Pieter Buma; B Willem Schreurs
Journal:  Acta Orthop       Date:  2014-09-19       Impact factor: 3.717

9.  Satisfying Results of Primary Hip Arthroplasty in Patients With Hip Dysplasia at a Mean Followup of 20 Years.

Authors:  Ena Colo; Wim H C Rijnen; Jean W M Gardeniers; Albert van Kampen; B Willem Schreurs
Journal:  Clin Orthop Relat Res       Date:  2016-08-04       Impact factor: 4.176

10.  Effect of intermittent administration of teriparatide on the mechanical and histological changes in bone grafted with β-tricalcium phosphate using a rabbit bone defect model.

Authors:  Jun Komatsu; Nana Nagura; Hideaki Iwase; Mamoru Igarashi; Osamu Ohbayashi; Isao Nagaoka; Kazuo Kaneko
Journal:  Exp Ther Med       Date:  2017-11-01       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.